Showing results (1-10 of 19) with videos related to
Sort By:
Pageof 2
Cytokine & Growth Factor Reviews|August 28, 1998
FLT3: receptor and ligand. Biology and potential clinical applicationM R Shurin, C Esche, M T LotzeForum (Genoa, Italy)|September 29, 2000
Cytokine-based therapy for melanoma: pre-clinical studiesM R Shurin, J M Kirkwood, C EscheCurrent Opinion in Molecular Therapeutics|March 16, 2001
The use of dendritic cells for cancer vaccinationC Esche, M R Shurin, M T LotzeProstate Cancer and Prostatic Diseases|December 24, 2002
TNF-alpha protects dendritic cells from prostate cancer-induced apoptosisG Pirtskhalaishvili, G V Shurin, C Esche, et al.Cancer Research|February 11, 1998
FLT3 ligand administration inhibits tumor growth in murine melanoma and lymphomaC Esche, V M Subbotin, C Maliszewski, et al.The British Journal of Dermatology|June 1, 1997
Muir-Torre syndrome: clinical features and molecular genetic analysisC Esche, R Kruse, C Lamberti, et al.Journal of Immunology (Baltimore, Md. : 1950)|December 2, 1998
FLT3-ligand administration inhibits liver metastases: role of NK cellsJ M Péron, C Esche, V M Subbotin, et al.Journal of Immunology (Baltimore, Md. : 1950)|September 8, 1999
Effect of vascular endothelial growth factor and FLT3 ligand on dendritic cell generation in vivoJ E Ohm, M R Shurin, C Esche, et al.The Prostate|February 15, 2001
Human prostate cancer regulates generation and maturation of monocyte-derived dendritic cellsM Aalamian, G Pirtskhalaishvili, A Nunez, et al.European Journal of Immunology|September 29, 2000
Interleukin-12 and Flt3 ligand differentially promote dendropoiesis in vivoC Esche, Q Cai, J M Peron, et al.Pageof 2